Toward the Treatment of Glioblastoma Tumors Using Photoactivated Chemotherapy: In Vitro Evaluation of Efficacy and Safety.

IF 3.7 Q1 CHEMISTRY, MEDICINAL ACS Pharmacology and Translational Science Pub Date : 2025-01-30 eCollection Date: 2025-02-14 DOI:10.1021/acsptsci.4c00600

Sina Katharina Goetzfried, Matthijs L A Hakkennes, Anja Busemann, Sylvestre Bonnet

{"title":"Toward the Treatment of Glioblastoma Tumors Using Photoactivated Chemotherapy: In Vitro Evaluation of Efficacy and Safety.","authors":"Sina Katharina Goetzfried, Matthijs L A Hakkennes, Anja Busemann, Sylvestre Bonnet","doi":"10.1021/acsptsci.4c00600","DOIUrl":null,"url":null,"abstract":"Glioblastoma multiforme (GBM) is highly aggressive, necessitating new therapies. Photoactivated chemotherapy (PACT) offers a promising approach by activating prodrugs with visible light at the tumor site. This study evaluated the anticancer activity of ruthenium-based PACT compounds in U-87MG glioblastoma cells and their safety in SH-SY5Y neuron-like cells. The compound [3](PF6)2 showed promising light-activated anticancer effects in U-87MG cells, while [1](PF6)2 was inactive, and [2](PF6)2 was nonactivated. Interestingly, in SH-SY5Y cells, light-activated [3](PF6)2 increased cell proliferation, similar to donepezil, without causing cell death. Increased Ca2+ uptake was observed, possibly via interaction with the AMPA receptor, as suggested by docking studies. These findings suggest ruthenium-based PACT compounds may serve as potential treatments for GBM, effectively attacking cancer cells while preserving healthy neuronal cells.","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"8 2","pages":"484-498"},"PeriodicalIF":3.7000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833736/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/acsptsci.4c00600","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/14 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Glioblastoma multiforme (GBM) is highly aggressive, necessitating new therapies. Photoactivated chemotherapy (PACT) offers a promising approach by activating prodrugs with visible light at the tumor site. This study evaluated the anticancer activity of ruthenium-based PACT compounds in U-87MG glioblastoma cells and their safety in SH-SY5Y neuron-like cells. The compound [3](PF₆)₂ showed promising light-activated anticancer effects in U-87MG cells, while [1](PF₆)₂ was inactive, and [2](PF₆)₂ was nonactivated. Interestingly, in SH-SY5Y cells, light-activated [3](PF₆)₂ increased cell proliferation, similar to donepezil, without causing cell death. Increased Ca²⁺ uptake was observed, possibly via interaction with the AMPA receptor, as suggested by docking studies. These findings suggest ruthenium-based PACT compounds may serve as potential treatments for GBM, effectively attacking cancer cells while preserving healthy neuronal cells.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

光活化化疗治疗胶质母细胞瘤：体外疗效和安全性评价。

多形性胶质母细胞瘤（GBM）具有高度侵袭性，需要新的治疗方法。光激活化疗（PACT）提供了一种很有前途的方法，通过在肿瘤部位用可见光激活前药。本研究评价了钌基PACT化合物对U-87MG胶质母细胞瘤细胞的抗癌活性及其对SH-SY5Y神经元样细胞的安全性。化合物[3](PF6)2在U-87MG细胞中表现出良好的光激活抗癌作用，而[1](PF6)2无活性，[2](PF6)2无活性。有趣的是，在SH-SY5Y细胞中，光激活[3](PF6)2增加细胞增殖，类似于多奈哌齐，而不引起细胞死亡。观察到Ca2+摄取增加，可能通过与AMPA受体的相互作用，正如对接研究所表明的那样。这些发现表明，基于钌的PACT化合物可能作为GBM的潜在治疗方法，有效地攻击癌细胞，同时保留健康的神经细胞。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ACS Pharmacology and Translational Science Medicine-Pharmacology (medical)

CiteScore

10.00

自引率

3.30%

发文量

133

期刊介绍： ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered. ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition. Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.